Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: A preliminary report of 434 patients

Urology

Volumn 51, Issue 5, 1998, Pages 796-803

  Sharkey, Jerrold ^a   Chovnick, Stanley D ^a   Behar, Raymond J ^a   Perez, Ramon ^a   Otheguy, Juan ^a   Solc, Zucel ^b   Huff, William ^c   Cantor, Alan ^d  

^a Urology Health Center   (United States)

^b West Coast Radiotherapy   (United States)

^c Medical Physicists   (United States)

^d Biostatistics Core   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; LEUPRORELIN; PALLADIUM; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER STAGING; ECHOGRAPHY; HUMAN; HUMAN TISSUE; IMPLANTATION; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; RADIATION DOSE; SCORING SYSTEM; TREATMENT OUTCOME; URINE INCONTINENCE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BRACHYTHERAPY; CHEMOTHERAPY, ADJUVANT; FLUTAMIDE; FOLLOW-UP STUDIES; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLADIUM; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 0031799434     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00017-X     Document Type: Article

References (22)

1. Whitmore WF Jr, Hilaris B, Grabstald H. Retropubic implantation of iodine 125 in the treatment of prostatic cancer. J Urol. 108:1972;918-920.
2. Porter AT. Prostate brachytherapy. Nucl Int. 22:1990;165-175.
3. Holms HH, Juul N, Pedersen JF. Transperineal 125 iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol. 130:1983;283-286.
4. Blasko JC, Wallner K, Grimm PD, Ragde H. Prostate specific antigen based disease control following ultrasound guided 125 iodine implantation for stage T1/T2 prostatic carcinoma. J Urol. 154:1995;1096-1099.
5. Stone NN, Forman JD, Sogani PC. Transrectal ultrasonography and I-125 implantation in patients with prostate cancer. J Urol. 139:1988;604A.
6. Stock RG, Stone NN, Wesson MF, DeWyngaert JK. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys. 32:1995;219-225.
7. Stone NN, Ramin SA, Wesson MF, Stock R, Unger P. Laparoscopic pelvic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate. J Urol. 153:1995;1555-1560.
8. Stone NN, Stock RG, DeWyngaert JK, Tabert A. Prostate brachytherapy improvements in prostate volume measurements and dose distribution using interactive ultrasound guided implantation and three-dimensional dosimetry . Radiat Oncol Invest. 3:1995;185-195.
9. Middleton RG, Thompson IM, Austenfeld MS, Cooner WH, Correa RJ, Gibbons RP, Miller HC, Oesterling JE, Resnick MI, Smalley SR, Wasson JH. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. J Urol. 154:1995;2144-2148.
10. Hendricks JG, Kaplan SA. What the literature reveals about the complications of radical retropubic prostatectomy. Contemp Urol. 9:1997;13-22.
11. Wallner KE, Roy J, Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 32:1995;465-471.
12. Zietman AJ, Prince EA, Nakfoor BM, Shipley WU. Neo-adjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate experimental and clinical results . Urology. 49:(suppl 3A):1997;74-83.
13. Pilepich MV, Krall JM, John MJ, Ruben P, Porter AT, Marceal VA, Martz KL. Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy preliminary results of RTOG 83-07 . Int J Radiat Oncol Biol Phys. 16:1989;813-817.
14. Zelefsky MJ, Harrison A. Neo-adjuvant androgen ablation prior to radiotherapy for prostate cancer reducing the potential morbidity of therapy . Urology. 49:(suppl 3A):1997;38-45.
15. Datoli M, Wallner K, Sorace R, Koval J, Cash J, Acosta R, Brown C, Etheridge J, Binder M, Brunelle R, et al. 103Pd brachytherapy and external-beam radiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys. 35:1996;875-879.
16. Consensus statement Guidelines for PSA following radiation therapy . Int J Radiation Oncol Biol Phys. 37:1997;1035-1041.
17. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol. 154:1995;456-459.
18. Abbas F, Scardino PT. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Urol Clin North Am. 23:1996;587-604.
19. Hanks GE. Long-term control of prostate cancer with radiation past, present, and future . Urol Clin North Am. 23:1996;605-616.
20. Goluboff ET, Benson MC. External beam radiation therapy does not offer long-term control of prostate cancer. Urol Clin North Am. 23:1996;617-621.
21. Zelefsky MJ, Whitmore WF Jr. Long-term results of retropubic permanent 125 iodine implantation of the prostate for clinically localized prostatic cancer. J Urol. 158:1997;23-30.
22. Reuter VE. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology. 49:(suppl 3A):1997;16-22.